A new screening tool that is being used to detect breast cancer is shown to work three times better than mammography at finding tumors in women who have dense tissue in their breast, which can confound mammograms. Mammography, which is an X-ray of the

The proposed ImClone Systems (IMCL) - Bristol Myers Squibb (BMY) merger remains somewhat of an enigma a month after the initial assessment. There are no substantial developments of note related to BMY's current offer, from either side, although there

Last week I blogged about Eli Lilly's (LLY) "Coming Soon" banner ad I spotted in the online edition of The New England Journal of Medicine. It's designed to generate buzz about the company's crucial new bloodthinner that could win Food and Drug

The telephone call comes from the St. Vincent De Paul food pantry at 809 North Lafayette Ave. in Evansville. A client needs his once-a-month allotment, but he has no transportation. Can the delivery team help? Bill Pigman, 79, stops what he's doing and

Almost seven percent of South African people age 20 or older have a personality disorder, an umbrella term for several personality types characterized by chronic social dysfunction, a large study funded by NIMH and others reveals. However, less than

WALES bucked the UK trend in the first half of this year by recording a rise in the value of corporate merger and acquisitions deals, according to new figures from Experian. While the number of mergers and acquisitions in Wales was down in the first

Are newer antidepressants really superior to benzodiazepines in the treatment of anxiety disorders? The current study uses a review of clinical research to question this assumption. Psychopharmacology

Pfizer and Bristol-Myers Squibb's apixaban has suffered a setback in trials against venous thromboembolism (VTE). An early evaluation of results from a phase III study investigating the prevention of VTE in patients undergoing knee replacement surgery

A radioactive tracer that "lights up" cancer hiding inside dense breasts showed promise in its first big test against mammograms, revealing more tumors and giving fewer false alarms, doctors reported Wednesday. The experimental method molecular breast

NEW YORK - Goldman Sachs and Co. downgraded ImClone Systems Inc. stock to "neutral" with a price target of $64 per share, near its current trading price. Get stories by e-mail on this topic. ImClone shares closed at $63.97 on Thursday. Analyst May-Kin